Answers are grounded in this paper and cite their sources.
Review highlights targeting age-specific immune pathways with precision adjuvants in pediatric populations, indicating new avenues to optimize vaccine durability and efficacy.
Elucidating optimal vaccine adjuvants for harnessing age-specific immune pathways to enhance magnitude, breadth, and durability of immunogenicity remains a key gap area in pediatric vaccine design. A better understanding of age-specific adjuvants will inform precision discovery and development of safe and effective vaccines for protecting children from preventable infectious diseases.
No takes yet. Share an insight, caveat, or question.
Boggiano et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: